These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32776377)

  • 1. US Food and Drug Administration regulatory approaches for xenotransplantation products and xenografts.
    Arcidiacono J
    Xenotransplantation; 2020 Nov; 27(6):e12626. PubMed ID: 32776377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid organ xenotransplantation at the interface between research and clinical development: Regulatory aspects.
    Schuurman HJ; Hoogendoorn K
    Xenotransplantation; 2020 May; 27(3):e12608. PubMed ID: 32500587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xenotransplantation: regulatory challenges.
    Bloom ET
    Curr Opin Biotechnol; 2001 Jun; 12(3):312-6. PubMed ID: 11404112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory changes in China on xenotransplantation and related products.
    Liu Y; Qin L; Tong R; Liu T; Ling C; Lei T; Zhang D; Wang Y; Deng S
    Xenotransplantation; 2020 May; 27(3):e12601. PubMed ID: 32372491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xenotransplantation of decellularized pig heart valves-Regulatory aspects in Europe.
    Godehardt AW; Tönjes RR
    Xenotransplantation; 2020 May; 27(3):e12609. PubMed ID: 32449225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction to the theme issue on regulatory aspects of xenotransplantation.
    Scobie L; Schuurman HJ
    Xenotransplantation; 2020 May; 27(3):e12620. PubMed ID: 32537837
    [No Abstract]   [Full Text] [Related]  

  • 7. US FDA to issue new rules on xenotransplantation.
    Novak K
    Nat Med; 1998 Aug; 4(8):876. PubMed ID: 9701227
    [No Abstract]   [Full Text] [Related]  

  • 8. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--chapter 1: Key ethical requirements and progress toward the definition of an international regulatory framework.
    Cozzi E; Tallacchini M; Flanagan EB; Pierson RN; Sykes M; Vanderpool HY
    Xenotransplantation; 2009; 16(4):203-14. PubMed ID: 19799760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New FDA xenotransplantation documents: a proposed rule and a draft guidance.
    Bloom ET
    Xenotransplantation; 2001 Aug; 8(3):153-4. PubMed ID: 11472622
    [No Abstract]   [Full Text] [Related]  

  • 10. Xenotransplantation--federal regulatory considerations.
    Bloom ET
    Curr Top Microbiol Immunol; 2003; 278():239-51. PubMed ID: 12934947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National policies for xenotransplantation in the USA.
    Bloom ET
    Xenotransplantation; 2007 Jul; 14(4):345-6. PubMed ID: 17669177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US guidelines on xenotransplantation.
    Nat Med; 1999 May; 5(5):465. PubMed ID: 10229206
    [No Abstract]   [Full Text] [Related]  

  • 13. Xenotransplantation under the Food and Drug Administration's Expanded Access pathway.
    Bobier C; Hurst DJ; Rodger D
    Am J Transplant; 2024 Oct; 24(10):1911-1912. PubMed ID: 38782186
    [No Abstract]   [Full Text] [Related]  

  • 14. Report of the Food and Drug Administration Subcommittee on Xenotransplantation: meeting of 13 January 2000, Center for Biologics Evaluation and Research.
    Xenotransplantation Subcommittee (Subcmomittee of the Biological Response Modifiers Advisory Commitee). Fod and Drug Administration,
    Xenotransplantation; 2000 May; 7(2):75-9. PubMed ID: 10961289
    [No Abstract]   [Full Text] [Related]  

  • 15. Report of the Food and Drug Administration Subcommittee on Xenotransplantation: meeting of 3 and 4 June, 1999, Center for Biologics Evaluation and Research.
    Auchincloss H
    Xenotransplantation; 1999 Nov; 6(4):232-7. PubMed ID: 10704066
    [No Abstract]   [Full Text] [Related]  

  • 16. US Public Health Service sets out plan for xenotransplantation.
    Hobbs MN
    Lancet; 1998 Jan; 351(9099):343. PubMed ID: 9652625
    [No Abstract]   [Full Text] [Related]  

  • 17. Medical devices: the obvious, the readily-accepted, and the surprising.
    Tolomeo DE; Clarke LA
    J Health Life Sci Law; 2008 Jul; 1(4):117, 119-44. PubMed ID: 18717154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Transplant Surgeons-American Society of Transplantation report of FDA meeting on regulatory expectations for xenotransplantation products.
    Adams A; Cendales LC; Cooper DKC; Cozzi E; Gill J; Judd E; Katz E; Kirk AD; Fishman JA; Reese PP; Wall A; Markmann JF
    Am J Transplant; 2023 Sep; 23(9):1290-1299. PubMed ID: 37217005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory barriers to xenotransplantation.
    Goerlich CE; Chan JL; Mohiuddin MM
    Curr Opin Organ Transplant; 2019 Oct; 24(5):522-526. PubMed ID: 31361629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment registration and listing for manufacturers of human cellular and tissue-based products--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(93):26744-55. PubMed ID: 10179343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.